Search results for " effect"

showing 10 items of 7524 documents

Current practice in regional anaesthesia in Germany

2005

Several new techniques and agents (e.g. ropivacaine) have been introduced in regional anaesthesia to improve patients outcome and safety. The beneficial effects on patient outcome are clear with these techniques, however, no information is available about their pattern and frequency of use in clinical practice. This study presents data concerning the current practice of regional anaesthesia in Germany.A questionnaire was sent to every German anaesthesia department (n = 1381). Questions focused on the frequency and range of regional anaesthetic procedures employed, with attention also to the organizational structural of the individual institution.Six hundred and sixty-seven questionnaires we…

medicine.medical_specialtyRopivacainebusiness.industryMEDLINERegional anaesthesiaAnesthesia departmentAnesthesiology and Pain MedicineAnesthesia ConductionCurrent practiceGermanySurveys and QuestionnairesAnesthesiamedicineHumansAnesthesia Department HospitalIntensive care medicinebusinessBeneficial effectsmedicine.drugEuropean Journal of Anaesthesiology
researchProduct

A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or …

2013

Abstract Background Myelofibrosis (MF) is a myeloproliferative neoplasm associated with progressive, debilitating symptoms that impact patient quality of life (QoL) and reduce survival. Ruxolitinib (RUX), a potent dual JAK1/JAK2 inhibitor, demonstrated superiority in spleen volume and symptom reduction, improved health-related QoL measures, and prolonged survival compared with traditional therapies or placebo in the phase 3 COMFORT studies. Panobinostat (PAN) is a potent oral pan-deacetylase inhibitor (DACi) that inhibits JAK pathway signaling through increased acetylation of the JAK2 protein chaperone HSP90. In phase 1/2 studies in MF, PAN has shown reduction in splenomegaly and JAK2 V617F…

medicine.medical_specialtyRuxolitinibbusiness.industryeducationImmunologyCell BiologyHematologymedicine.diseasePlaceboOff-label useBiochemistryDiscontinuationInternational Prognostic Scoring SystemInternal medicineCohortImmunologymedicineMyelofibrosisbusinessAdverse effecthealth care economics and organizationsmedicine.drugBlood
researchProduct

Thyroid hormones induce sumoylation of the cold shock domain-containing protein PIPPin in developing rat brain and in cultured neurons.

2006

We previously identified a cold shock domain (CSD)-containing protein (PIPPin), expressed at high level in brain cells. PIPPin has the potential to undergo different post-translational modifications and might be a good candidate to regulate the synthesis of specific proteins in response to extracellular stimuli. Here we report the effects of thyroid hormone (T3) on PIPPin expression in developing rat brain. We found that a significant difference among euthyroid- and hypothyroid- newborn rats concerns sumoylation of nuclear PIPPin, that is abolished by hypothyroidism. Moreover, T3-dependence of PIPPin sumoylation has been confirmed in cortical neurons purified from brain cortices and culture…

medicine.medical_specialtySUMO-1 ProteinSUMO proteinDeveloping rat brainNerve Tissue ProteinsEndocrinologyAntithyroid AgentsHypothyroidismPregnancyInternal medicinemedicineExtracellularAnimalsRats WistarCells CulturedCell NucleusCerebral CortexNeuronsbiologyRNA-Binding ProteinsCold-shock domainChromatinProtein Structure TertiaryRatsThyroid hormoneChemically defined mediumCell nucleusmedicine.anatomical_structureHistoneEndocrinologyAnimals NewbornPropylthiouracilPrenatal Exposure Delayed Effectsbiology.proteinTriiodothyronineRNA-binding proteins (RBPs)FemaleRabbitsNucleusEndocrinology
researchProduct

Effects of intravenous furosemide plus small-volume hypertonic saline solutions on markers of heart failure.

2021

Aims: We sought to compare the effects of furosemide + hypertonic saline solution (HSS) treatment in patients with acute decompensated heart failure in comparison with furosemide alone and the response in a compensated state after an acute saline load with regard to serum levels of heart failure biomarkers. Methods and results: We enrolled 141 patients with acute decompensated heart failure with reduced ejection fraction admitted to our Internal Medicine ward from March 2017 to November 2019. A total of 73 patients were randomized to treatment with i.v. high-dose furosemide plus HSS, whereas 68 patients were randomized to i.v. high-dose furosemide alone. Patients treated with furosemide plu…

medicine.medical_specialtySettore MED/09 - Medicina InternaAcute decompensated heart failuremedicine.medical_treatmentfurosemide Heart failure HSS BiomarkersGastroenterologyFurosemideInternal medicineOriginal Research ArticlesmedicineDiseases of the circulatory (Cardiovascular) systemHumansOriginal Research ArticleHSSDiureticsSalineHeart FailureSaline Solution HypertonicEjection fractionTroponin Tbusiness.industryTherapeutic effectFurosemideAcute decompensated heart failuremedicine.diseaseHypertonic salineRC666-701Heart failureCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugESC heart failure
researchProduct

Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental s…

2016

We have reviewed the safety and tolerability of β3-adrenoceptor agonists, specifically mirabegron and solabegron, a newly emerging drug class for the treatment of the overactive bladder syndrome. We discuss them mechanistically in the context of expression and other preclinical data.Based on a systematic PubMed search, incidence of overall adverse events, hypertension, dry mouth, and constipation are comparable between mirabegron or solabegron and placebo. Hypertension is the most frequently observed adverse event, but has a similar incidence with mirabegron and placebo. Nevertheless, severe uncontrolled hypertension has become a contraindication for use of mirabegron based on observation o…

medicine.medical_specialtySide effect030232 urology & nephrologyUrologyContext (language use)Adrenergic beta-3 Receptor AgonistsBenzoates03 medical and health sciences0302 clinical medicineSolabegronmedicineAnimalsHumansPharmacology (medical)Adverse effectAniline Compoundsbusiness.industryUrinary Bladder OveractiveGene Expression ProfilingBiphenyl CompoundsGeneral MedicineBiphenyl compoundThiazolesTolerability030220 oncology & carcinogenesisAnesthesiaReceptors Adrenergic beta-3AcetanilidesTolterodinebusinessMirabegronmedicine.drugExpert opinion on drug safety
researchProduct

Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular s…

2021

Introduction: The newest intravenous (IV) iron products show an improved safety profile over predecessors, allowing for the rapid administration of relatively high doses. Ferric derisomaltose (FDI; also known as iron isomaltoside), ferric carboxymaltose (FCM), and ferumoxytol (FER), are successful treatments for iron deficiency (Europe; FDI and FCM) and iron deficiency anemia (US; FDI, FCM, and FER).Areas covered: This review focusses on the chemistry and structure of FDI, FCM, and FER, and on three key aspects of IV iron safety: (1) hypersensitivity; (2) hypophosphatemia and sequelae; (3) cardiovascular safety.Expert opinion: Although the safety of modern IV iron has improved, immediate in…

medicine.medical_specialtySide effectAnemiaHypophosphatemia030204 cardiovascular system & hematologyDrug Hypersensitivity03 medical and health sciences0302 clinical medicinemedicineHumansPharmacology (medical)Intensive care medicineAnemia Iron-Deficiencybusiness.industryGeneral MedicineIron deficiencymedicine.diseaseFerumoxytolIron-deficiency anemiaCardiovascular Diseases030220 oncology & carcinogenesisFerricAdministration IntravenousbusinessAnaphylaxisHypophosphatemiaIron Compoundsmedicine.drugExpert opinion on drug safety
researchProduct

Management options for low-dose methotrexate-induced oral ulcers : a systematic review

2019

Background Oral ulcers caused by methotrexate (MTX) at low doses are a known side effect of this drug. Although increasingly more patients are medicated with MTX, these painful ulcers, without traumatic origin and resistant to any type of treatment, are not usually identified by health professionals as a side effect of the medication. Material and Methods In the absence of a consensus protocol for the effective treatment of oral lesions produced by MTX, the objective of this article was to review and analyse the information from articles related to oral ulcers produced by low-dose MTX and to record the clinical management performed and the MTX dose given to the patient. Data sources - Medli…

medicine.medical_specialtySide effectDatabases FactualPsychological interventionMEDLINEAdministration OralReviewCochrane Library03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansGeneral DentistryOral UlcerProtocol (science)Oral Medicine and Pathologybusiness.industry030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Systematic reviewMethotrexateTreatment OutcomeOtorhinolaryngologySample size determinationUNESCO::CIENCIAS MÉDICASSurgeryBradford Hill criteriabusiness
researchProduct

A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis

2021

Abstract Denosumab is associated with the development of medication-related osteonecrosis of the jaw (MRONJ), an uncommon but severe oral side effect with a higher prevalence in metastatic cancer patients than in patients with metabolic bone fragility. Although several oral triggers can initiate MRONJ, invasive oral treatments and tooth extraction still remain the most common precipitating event. In general, tooth extraction and oral surgery should be avoided in patients at increased risk of MRONJ, while extraction of non-restorable teeth should be performed based on specific risk reduction protocols to eliminate dental/periodontal infections, still protecting from MRONJ onset. Based on th…

medicine.medical_specialtySide effectOsteoporosisSpecialties of internal medicine030209 endocrinology & metabolismMRONJOral surgery tooth extraction03 medical and health sciences0302 clinical medicineOral surgeryMedication-related osteonecrosis of the jawmedicineDenosumab osteoporosis; Medication-related osteonecrosis of the jaw; MRONJ; Oral surgery tooth extraction; Denosumab; Diphosphonates; Humans; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; OsteoporosisHumansIntensive care medicineGeneral Dentistrytooth extractionBisphosphonate-associated osteonecrosis of the jawDiphosphonatesBone Density Conservation Agentsbusiness.industryHypothesismedicine.diseaseosteoporosisDenosumab osteoporosisBone Density Conservation Agentsstomatognathic diseasesDenosumabOtorhinolaryngologyRC581-951030220 oncology & carcinogenesisDental surgeryOral and maxillofacial surgeryBisphosphonate-Associated Osteonecrosis of the JawNeurology (clinical)DenosumabbusinessOsteonecrosis of the jawmedicine.drugHead & Face Medicine
researchProduct

Determination of crown discoloration and fluorescence induced by different medications used in regenerative endodontic procedures: An ex vivo study

2021

Background Crown discoloration is an undesirable side effect of the use of triple antibiotic paste (TAP) in regenerative endodontic procedures (REPs). The aim of this ex vivo study was to assess the potential for tooth discoloration and induction of fluorescence associated with the use of TAP containing either doxycycline (DOX) or clindamycin (CLIN), and of calcium hydroxide (Ca(OH)2), by spectrophotometric analysis and confocal laser scanning microscopy (CLSM). Material and methods A total of forty single-rooted human teeth extracted by therapeutic indication were used. The root canals were enlarged using the step-back technique up to a K #80 file and were randomly divided into four experi…

medicine.medical_specialtySide effectRestauració dentalRoot canalmedicine.medical_treatmentCalcium hydroxideAntibiòticsHidròxid de calciPharmacologyCrown (dentistry)Operative Dentistry and EndodonticsEndodonticsTooth discolorationchemistry.chemical_compoundAntibioticsmedicineEsmalt dentalDental enamelEndodònciaGeneral DentistryUNESCO:CIENCIAS MÉDICASDoxycyclineCalcium hydroxideResearchEndodonticsDental Restorationmedicine.anatomical_structurechemistryEx vivomedicine.drugJournal of Clinical and Experimental Dentistry
researchProduct

Indomethacin treatment in amphotericin B induced nephrogenic diabetes insipidus.

1994

Nephrogenic diabetes insipidus (NDI) is a serious side effect of various drugs. Elevated renal prostaglandin E2 levels have been found in patients with lithium-induced NDI and have been implicated in the pathogenesis. We report the case of a patient who developed NDI following treatment with amphotericin B. Prostaglandin levels were elevated. Indomethacin had an antidiuretic effect and normalized prostaglandin levels.

medicine.medical_specialtySide effectVasopressinsIndomethacinProstaglandinDiabetes Insipidus NephrogenicKidneyLeukemia Myelomonocytic AcutePathogenesischemistry.chemical_compoundAmphotericin BInternal medicineAmphotericin BDrug DiscoveryMedicineHumansProstaglandin E2Genetics (clinical)business.industryGeneral MedicineMiddle Agedmedicine.diseaseNephrogenic diabetes insipidusDiuresisEndocrinologychemistryDiabetes insipidusToxicityProstaglandinsTobramycinMolecular Medicinelipids (amino acids peptides and proteins)Femalebusinessmedicine.drugThe Clinical investigator
researchProduct